NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00091442,A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT00091442,,COMPLETED,The purpose of the study is to evaluate whether the time to progression for the DOXIL and docetaxel combination therapy group was superior to that of the group treated with docetaxel monotherapy in participants with advanced breast cancer.,YES,Breast Cancer,DRUG: Docetaxel|DRUG: DOXIL,"Time to Progression, Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first., From date of randomization until date of disease progression or death, whichever occurred first, until approximately 485 events of disease progression or death were observed, as assessed approximately 15 months after the last patient was enrolled","Overall Survival, Time interval in months between the date of randomization and the participant's death from any cause., From the date of randomization until the participant's death from any cause, as assessed until approximately 485 death events were observed which is assessed approximately 25 months after the last patient was enrolled|Response Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR), Number of participants in the evaluable population who achieved a CR or PR as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR: Disappearance of all target lesions and PR: at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. Response was assessed by Computed Tomography (CT)/Magnetic Resonance Imaging (MRI)., Up to 30 to 42 days after last dose of study medication",,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,FEMALE,"ADULT, OLDER_ADULT",PHASE3,751,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CR004120|DOXILBCA3001,2004-09,2008-12,2008-12,2004-09-13,2012-10-02,2014-04-21,"Hoover, Alabama, United States|Fountain Valley, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Palm Springs, California, United States|Newark, Delaware, United States|Lakeland, Florida, United States|Fort Gordon, Georgia, United States|Centralia, Illinois, United States|Joliet, Illinois, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Lafayette, Louisiana, United States|Baltimore, Maryland, United States|Jackson, Mississippi, United States|Las Vegas, Nevada, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Cooperstown, New York, United States|New York, New York, United States|Gastonia, North Carolina, United States|Philadelphia, Pennsylvania, United States|Upland, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|N Charleston, South Carolina, United States|Fort Worth, Texas, United States|Pasadena, Texas, United States|Plovdiv, Bulgaria|Shumen, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Tartu N/A, Estonia|Rabat, France|Tunis, France|Budapest N/A, Hungary|Budapest, Hungary|Debrecen, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Zalaegerszeg, Hungary|Ashkelon, Israel|Haifa, Israel|Jerusalem, Israel|Ramat-Gan, Israel|Tel Aviv, Israel|Riga, Latvia|Kaunas, Lithuania|Vilnius, Lithuania|Arnhem, Netherlands|Capelle Aan Den Ijssel, Netherlands|Den Haag, Netherlands|Roosendaal, Netherlands|Bialystok, Poland|Bydgoszcz, Poland|Bytom, Poland|Gdansk, Poland|Gdynia N/A, Poland|Gliwice, Poland|Kielce, Poland|Koszalin, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Olsztyn, Poland|Poznan, Poland|Warsaw, Poland|Coimbra, Portugal|Matosinhos N/A, Portugal|Bacau, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Hunedoara, Romania|Iasi, Romania|Onesti, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Balashikha, Russian Federation|Barnaul, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Engels Saratov Region, Russian Federation|Irkutsk, Russian Federation|Ivanovo, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Leningrad Region, Russian Federation|Lipetsk, Russian Federation|Moscow N/A, Russian Federation|Moscow Region, Russian Federation|Moscow, Russian Federation|Murmansk, Russian Federation|N Novgorod N/A, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Obninsk, Russian Federation|Omsk, Russian Federation|Orel, Russian Federation|Petrozavodsk, Russian Federation|Pyatigorsk, Russian Federation|Rostov-Na-Donu, Russian Federation|Ryazan, Russian Federation|Samara N/A, Russian Federation|Smolensk, Russian Federation|St Petersburg N/A, Russian Federation|St. Petersburg, Russian Federation|Stavropol, Russian Federation|Tomsk, Russian Federation|Tver, Russian Federation|Ulianovsk, Russian Federation|Vladimir, Russian Federation|Volgograd, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Beograd, Serbia|Nis, Serbia|Sremska Kamenica, Serbia|Cape Town, South Africa|Johannesburg, South Africa|Kimberley, South Africa|Parktown, South Africa|Port Elizabeth, South Africa|Pretoria Gauteng, South Africa|Pretoria, South Africa|Bilbao Vizcaya, Spain|LÃ©rida, Spain|Madrid, Spain|Santander N/A, Spain|Sevilla, Spain|Cherkassy, Ukraine|Chernivtsi, Ukraine|Dnepropetrovsk, Ukraine|Donetsk, Ukraine|Kharkov, Ukraine|Kiev, Ukraine|Lugansk, Ukraine|Lutsk, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Simferopol, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Zhitomir, Ukraine|Huddersfield, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom|Sutton, United Kingdom",
